Freedom from castration: An alternative end point for men with localized prostate cancer treated by external beam radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 5, 2002, Pages 1152-1159

  Zietman, Anthony ^a   Thakral, Harjot ^a   Skowronski, Uri ^a   Shipley, William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgen deprivation; Prostate cancer; Radiotherapy; Watchful waiting

Indexed keywords

BIOCHEMICAL ENGINEERING; PATIENT MONITORING; RADIOGRAPHY; TUMORS;

BIOCHEMICAL FAILURE; CASTRATION;

RADIOTHERAPY;

ANDROGEN; ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BEAM THERAPY; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOGRAPHY; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036680351     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02858-4     Document Type: Article

References (27)

1. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer
2. Results of conservative management of clinically localized prostate cancer
3. High 10-year survival rate in patients with early, untreated prostate cancer
4. Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden
5. Deferred treatment of clinically localized low grade prostate cancer: The experience from a prospective series at the Karolinska Hospital
6. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer
7. Duration of pre-clinical prostate cancer based on serial PSA data from the VA Normative Aging Study
8. A comparison of treatment recommendations for men with clinically localized prostate cancer by urologists and radiation oncologists
9. Expectant management of clinically localized prostatic cancer
10. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
11. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: A national survey of urologist beliefs and practices
12. Conservative management of prostate cancer in the PSA era: The incidence and time course of subsequent therapy
13. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy
14. Nonparametric estimation from incomplete observations
15. Statistical aspects of the analysis of data from retrospective studies of disease
16. The treatment of prostate cancer by conventional radiation therapy: An analysis of long term outcome
17. 20 Years of progress in radiation oncology: Prostate cancer
18. Natural history of localized prostatic cancer managed by conservative therapy alone
19. Prospective, conservative management of localized prostate cancer
20. Deferred treatment for prostate cancer
21. If you "watch and wait" prostate cancer may progress dramatically
22. Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database
23. Natural history of progression after PSA elevation following radical prostatectomy
24. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
25. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study
26. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations
27. Bicalutamide 150 mg mono-therapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multi-center randomized trials at median follow-up of 4 years